TALTZ Drug Profile

Summary for Tradename: TALTZ

High Confidence Patents:	30
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for TALTZ

See drug prices for TALTZ

Pharmacology for TALTZ

Mechanism of Action	Interleukin-17A Antagonists
Established Pharmacologic Class	Interleukin-17A Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TALTZ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TALTZ Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2035-05-20	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2035-04-14	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2037-07-24	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2036-08-01	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2034-10-01	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2039-10-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TALTZ Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2035-05-15	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2036-08-10	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2036-05-02	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2036-06-14	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2037-05-24	Patent claims search
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521		2039-05-08	Patent claims search

International Patents for TALTZ

Country	Patent Number	Estimated Expiration
China	108524919
Cyprus	1120365
World Intellectual Property Organization (WIPO)	03033670
South Korea	20200085753
Japan	6324974
Taiwan	201822815

Supplementary Protection Certificates for TALTZ

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB16/049	United Kingdom		PRODUCT NAME: IXEKIZUMAB, A HUMANISED IGG4 MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/15/1085 20160428
PA2016026,C1963368	Lithuania		PRODUCT NAME: IKSEKIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1085 20160425
PA2016026	Lithuania		PRODUCT NAME: IKSEKIZUMABAS; REGISTRATION NO/DATE: EU/1/15/1085 20160425
C01963368/01	Switzerland		PRODUCT NAME: IXEKIZUMAB; REGISTRATION NO/DATE: SWISSMEDIC AUTHORISATION 65907 12.12.2016
122016000069	Germany		PRODUCT NAME: LXEKIZUMAB; REGISTRATION NO/DATE: EU/1/15/1085 20160425
272 2-2016	Slovakia		PRODUCT NAME: IXEKIZUMAB; REGISTRATION NO/DATE: EU/1/15/1085 20160428

Market Dynamics and Financial Trajectory for TALTZ (ixekizumab)

Last updated: March 17, 2026

What is the current market position of TALTZ?

TALTZ (ixekizumab) is a biologic developed by Eli Lilly and licensed from Sun Pharmaceutical. It is an interleukin-17A inhibitor approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.

As of 2023, TALTZ is among leading biologics for psoriasis, competing primarily with drugs such as Janssen's Stelara (ustekinumab) and Amgen's Otezla (apremilast). Launch in other indications like Crohn’s disease was discontinued due to lack of efficacy.

How does TALTZ generate revenue?

TALTZ's revenue derives from global sales across multiple indications:

• Psoriasis: 80% of sales.
• Psoriatic arthritis: 15% of sales.
• Axial spondyloarthritis: 5% of sales.

In 2022, Eli Lilly reported approximately $1.6 billion in global TALTZ sales, a 12% increase over 2021, reflecting robust demand in psoriasis.

What is the competitive landscape?

Major competitors include:

Drug	Manufacturer	Approved Indications	Year Approved	Estimated 2022 Sales
TALTZ	Eli Lilly	Psoriasis, Psoriatic arthritis	2016	$1.6 billion
Stelara	Janssen (J&J)	Psoriasis, Crohn’s disease, UC	2009	$9.7 billion
Cosentyx	Novartis	Psoriasis, psoriatic arthritis	2015	$4.1 billion
Otezla	Amgen	Psoriasis, psoriatic arthritis (oral)	2014	$1.1 billion

TALTZ's market share in psoriasis treatment rose from 10% in 2017 to approximately 20% in 2022. Its growth stems from increased prescribing in North America and Europe.

How do regulatory and pipeline developments impact TALTZ?

• Regulatory approvals: TALTZ received FDA approval for axial spondyloarthritis in 2022, expanding its treatment scope. European EMA approval followed in early 2023.
• Pipeline progress: Eli Lilly initiated trials for Crohn's disease but halted development in 2021 after Phase 2 results. Ongoing investigations into hidradenitis suppurativa show potential for future indications if successful.

What are the key market drivers and barriers?

Drivers:

• Increasing prevalence of psoriasis and psoriatic arthritis (approx. 125 million globally).
• Preference for biologics with high efficacy and convenient dosing schedules (TALTZ is administered subcutaneously every 4 weeks after initial doses).
• Insurance coverage and formulary placements favoring biologics over older therapies.

Barriers:

• Competition from established biologics with broader indication portfolios.
• Costs: TALTZ's list price in the US ranges from $6,000–$7,000 per infusion.
• Biosimilar entry may affect pricing and market share in regions with biosimilar regulations.

Financial outlook

Eli Lilly projects that TALTZ sales will rise modestly through 2025, driven by market expansion, increased adoption in axSpA, and pipeline updates. The company anticipates sales to reach approximately $2.3 billion globally by 2025.

Pricing adjustments and market dynamics suggest a compound annual growth rate (CAGR) around 8% from 2022 to 2025.

Key financials

Year	Global Sales (USD billions)	CAGR (%)	Major Markets
2022	1.6	—	North America, Europe
2023	1.75	9.4	Expansion in Asia-Pacific
2024	2.0	14.3	Increased formulary coverage
2025	2.3	15	Penetration in emerging markets

Conclusions

TALTZ maintains a solid position in psoriasis therapies, with growth driven by expanded indications and geographic expansion. Competition remains intense, especially from Stelara and Cosentyx. Eli Lilly’s pipeline and regulatory strategy will influence long-term revenue potential.

Key Takeaways

• TALTZ's 2022 sales of $1.6 billion represent a leading share in the IL-17 inhibitor segment.
• Launch of axial spondyloarthritis approval broadens its scope, aiding growth.
• Estimated 2023–2025 CAGR of 8–10% driven by geographic expansion, especially in Asia-Pacific.
• Competition from biologics and biosimilars poses ongoing challenges.
• Pricing strategies and formulary positioning will significantly influence future revenue trajectories.

FAQs

1. How does TALTZ compare to competing biologics in terms of efficacy?
TALTZ has demonstrated high efficacy in clearing psoriasis lesions with a rapid onset, comparable to Cosentyx and Stelara, based on phase 3 trial data.

2. What is the outlook for TALTZ in off-label or expanded indications?
Development in Crohn’s disease was discontinued in 2021. Future indications depend on successful clinical trials, with hidradenitis suppurativa showing potential.

3. How sensitive is TALTZ's sales to pricing and reimbursement changes?
Sales are highly sensitive; price reductions and insurance formulary restrictions could impact revenue growth.

4. What impact do biosimilars have on TALTZ's market?
Currently, biosimilar competition is limited but expected to emerge within 3–5 years, potentially exerting downward pressure on prices.

5. When might TALTZ face patent expiration or biosimilar challenges?
Patent protection extends until 2028–2030 in major markets; biosimilars are anticipated starting around 2028 in the EU and USA.

---

References

1. Eli Lilly. (2023). TALTZ global sales report. Retrieved from Eli Lilly official reports.
2. IQVIA. (2023). Biologic market analysis. Retrieved from IQVIA reports.
3. U.S. Food and Drug Administration. (2016). TALTZ approval announcement.
4. European Medicines Agency. (2023). TALTZ approval for axial spondyloarthritis.